- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01558115
Denosumab in Primary Hyperparathyroidism
Primary hyperparathyroidism (PHPT), a disease characterized by excess parathyroid hormone (PTH) and high blood calcium, is one of the most common endocrine disorders. PHPT is seen most often in postmenopausal women. Many patients with PHPT have low bone mineral density (BMD) when bone mass is measured by dual energy x-ray absorptiometry (DXA), primarily at the forearm. There is currently no effective medical therapy which increases bone density at the forearm in patients with PHPT.
PTH both builds and breaks down bone, and the pathways by which PTH mediates these actions are beginning to be identified. Prior research suggests that RANKL, a molecule important in bone metabolism, responds to PTH, and that if the RANKL is inactivated, PTH is shifted towards building bone. The investigators will study the effect of Denosumab, a therapeutic agent that binds to and inactivates RANKL, in 28 postmenopausal women with PHPT. Our hypothesis is that Denosumab will increase bone mineral density in primary hyperparathyroidism.
The study will last two years, and subjects will be randomly assigned to receive either placebo or Denosumab for the first year of the study. In the second year, all subjects will receive Denosumab. Denosumab (60 mg) or placebo will be given every 6 months by an injection just under the skin. Study procedures performed will include bone mineral density tests by DXA, high-resolution peripheral quantitative computed tomography (HR-pQCT) scans, and assessments of biochemical markers of calcium metabolism and bone turnover using both blood and urine samples of subjects with PHPT.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PTH has both catabolic and anabolic properties, and under normal circumstances, PTH in PHPT is catabolic for bone at the cortical skeleton. Recently, evidence for a direct role of PTH on RANKL expression and osteoclastogenesis in vivo was obtained using mice lacking a distant transcriptional enhancer of the RANKL gene that confers responsiveness to PTH. These observations, supported by additional cross-sectional studies in human subjects make a compelling argument that the catabolic actions of PTH are mediated by RANKL-mediated bone resorption.
The investigators now propose a proof of concept study to test the hypothesis that in PHPT, inhibition of the RANK-L pathway will unmask the anabolic potential of PTH. A therapeutic agent that redirects the actions of PTH in PHPT from one that is primarily catabolic to an anabolic one would fulfill this proof of concept. The investigators hypothesize that Denosumab, a human Immunoglobulin G (IgG) antibody that binds to and inactivates RANKL, will convert skeletal actions of PTH from catabolic to anabolic in primary hyperparathyroidism.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed hypercalcemic PHPT in postmenopausal women with serum calcium >10.2 mg/dL and < 12.0 mg/dL (nl: 8.6-10.2)
- T-score between -1.5 and -2.5 at any site. If the T-score is <-2.5, patients become candidates for parathyroid surgery. They will be enrolled only if they refuse the parathyroid surgery
Exclusion Criteria:
- 25-hydroxyvitamin D level < 20 ng/ml
- Previous use of the bisphosphonate zoledronic acid (ever), alendronate or risedronate (within 12 months) or ibandronate (within 6 months)
- Current use of PTH, glucocorticoids, SERMS, estrogen (other than vaginal), calcitonin or pharmacological amounts of calcitriol Current or previous use of cinacalcet (within 6 months)
- Hyperthyroidism
- Rheumatoid arthritis or any other inflammatory joint disease
- Paget's disease of bone
- Malabsorption
- T-score <-3.5 at any site
- Signs of symptomatic PHPT (e.g, kidney stones within the past 5 years; fragility fracture within the past 2 years)
- Physical or mental handicapping condition that precludes ability to complete the protocol and/or provide informed consent.
- Subjects on Antiviral HIV therapy or subjects with compromised immune systems
- Premenopausal women or men
- Stage 5 Chronic Kidney Disease (CKD) or anyone on dialysis
- Creatinine clearance < 30 cc/min unless the patient is not a candidate for surgery or if the patient refuses surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Denosumab - Group #1
Receive active drug for year 1 and year 2 of the study
|
The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2. Group # 1: Receive active drug for year 1 and year 2 of the study Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Other Names:
|
Placebo Comparator: Placebo - Group #2
Receive placebo for year 1 and active drug for year 2 of the study
|
The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2. Group # 1: Receive active drug for year 1 and year 2 of the study Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Other Names:
The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval. The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2. Group # 1: Receive active drug for year 1 and year 2 of the study Group #2: Receive placebo for year 1 and active drug for year 2 of the study |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bone Mineral Density (BMD) at the Lumbar Spine
Time Frame: Baseline and 12 months
|
Percent change from baseline in BMD at the lumbar spine, as measured by Dual-emission X-ray absorptiometry (DXA) scan at 12 months
|
Baseline and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bone Mineral Density (BMD) at the Distal 1/3 Radius
Time Frame: 12 months
|
Percent change from baseline in BMD at the distal 1/3 radius, as measured by Dual-emission X-ray absorptiometry (DXA) scan at 12 months
|
12 months
|
Change in Bone Mineral Density (BMD) at the Hip
Time Frame: 12 months
|
Percent change from baseline in BMD at the hip, as measured by Dual-emission X-ray absorptiometry (DXA) scan at 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John P Bilezikian, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAF2568
- R01DK032333 (NIH)
- 20090741 (Other Identifier: Amgen)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Hyperparathyroidism
-
Postgraduate Institute of Medical Education and...UnknownPrimary Hyperparathyroidism (PHPT)India
-
Nantes University HospitalCompleted
-
Rambam Health Care CampusWithdrawnMultigland Disease in Primary HyperparathyroidismIsrael
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedTotal Thyroidectomy | Bilateral Neck Exploration for Primary HyperparathyroidismUnited Kingdom
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Brigham and Women's HospitalCompletedPrimary HyperparathyroidismUnited States
-
University Hospital Inselspital, BerneCompletedPrimary HyperparathyroidismSwitzerland
-
EFSTATHIOS CHRONOPOULOSCompletedPrimary Hyperparathyroidism
-
M.D. Anderson Cancer CenterUnknownPrimary HyperparathyroidismUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownPrimary Hyperparathyroidism
Clinical Trials on Denosumab
-
AmgenCompletedOsteoporosis | Osteopenia | Low Bone Mineral Density | Low Bone Mass | Males With Osteoporosis
-
GlaxoSmithKlineCompletedOsteoporosis, PostmenopausalKorea, Republic of
-
AmgenCompletedPostmenopausal OsteoporosisUnited States, Denmark, Poland, Canada
-
AmgenCompletedHealthy VolunteerUnited States
-
Samsung Bioepis Co., Ltd.CompletedPostmenopausal OsteoporosisPoland
-
Luye Pharma Group Ltd.ParexelCompleted
-
Borstkanker Onderzoek GroepAmgenWithdrawn
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
National Cancer Institute (NCI)TerminatedOvarian CarcinomaUnited States, Israel